Capricor Investor News: If You Have Suffered Losses in Capricor Therapeutics Inc., You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Capricor Therapeutics Inc. (NASDAQ: CAPR) resulting from allegations that Capricor may have issued materially misleading business information to the investing public.

If you purchased Capricor securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

To join the prospective class action, go to https://rosenlegal.com/cases/capricor-therapeutics-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

On July 27, 2026, Reuters published an article entitled "FDA staff flags data concerns about Capricor's therapy; shares plunge". The article stated that FDA "staff reviewers raised concerns about the effectiveness data for Capricor Therapeutics' cell therapy for a heart condition related to Duchenne muscular dystrophy, dragging the company's ‌shares 65% lower in early trading." Further, the " briefing documents, released on Monday, mention the effectiveness and risk-benefit profile of the experimental therapy, deramiocel, to be discussed at the FDA's external advisers' meeting on Wednesday." On this news, Capricor shares fell 64% on July 27, 2026.